Introduction Management of alcohol use disorder in patients with cirrhosis remains a clinical challenge, where drug safety is as critical as efficacy. Acamprosate is generally preferred due to renal clearance, while baclofen has been considered safe even in advanced liver disease.
Introduction
Management of alcohol use disorder in patients with cirrhosis remains a clinical challenge, where drug safety is as critical as efficacy. Acamprosate is generally preferred due to renal clearance, while baclofen has been considered safe even in advanced liver disease. However, comparative real-world safety data between these two commonly used agents in compensated alcohol-associated cirrhosis have been limited.
Problem Statement
Despite guideline endorsement of both baclofen and acamprosate, uncertainty persists regarding their relative hepatic safety. Clinicians often face a dilemma in choosing therapy, particularly in patients at risk of decompensation, where even small differences in adverse outcomes can significantly impact prognosis.
Summary
This large, multicenter, real-world cohort study using a target trial emulation framework compared baclofen and acamprosate in compensated alcohol-associated cirrhosis. After robust propensity matching, baclofen was associated with a higher incidence of major adverse liver outcomes at one year compared to acamprosate (34.3% vs 27.4%). Notably, the increased risk was primarily driven by a higher incidence of hepatic encephalopathy, while other decompensation events and mortality did not differ significantly. The risk appeared more pronounced in older patients.
These findings suggest that while baclofen remains an option, acamprosate may be the safer first-line agent in compensated cirrhosis, particularly in patients at risk for encephalopathy. This study provides important real-world evidence to guide individualised therapeutic decision-making in this vulnerable population.
Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...
Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.